Asthma is a heterogeneous lung disease with variable phenotypes (clinical presentations)
and distinctive endotypes (mechanisms). Over the last decade, considerable efforts have …

Asthma treatment goals currently focus on symptom and exacerbation control rather than
remission. Remission is not identical to cure, but is a step closer. This review considers the …

Bronchial asthma (BA) is a chronic inflammatory disease with a marked heterogeneity in
pathophysiology and etiology. The heterogeneity of BA may be related to the inducing …

Inflammation, structural, and functional abnormalities within the airways are key features of
asthma. Although these processes are well documented, their expression varies across the …

Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …

abstract IgE and mast cells play a pivotal role in various allergic diseases, including asthma,
allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody …

Asthma is a heterogenous disease characterized by multiple phenotypes driven by different
mechanisms. The implementation of precision medicine in the management of asthma …

The lacrimal film has attracted increasing interest in the last decades as a potential source of
biomarkers of physiopathological states, due to its accessibility, moderate complexity, and …

Asthma is a disorder of the airways involving various inflammatory cells and mediators and
characterised by bronchial hyperresponsiveness, chronic inflammation and structural …

At present, there is no cure for asthma, and treatment typically involves therapies that
prevent or reduce asthma symptoms, without modifying the underlying disease. A “disease …